<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874897</url>
  </required_header>
  <id_info>
    <org_study_id>CT041-CG4006</org_study_id>
    <nct_id>NCT03874897</nct_id>
  </id_info>
  <brief_title>Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.</brief_title>
  <official_title>An Open Lable, Dose Escalating/Dose Regimen Finding Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CARsgen Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, dose escalating/dose regimen finding clinical study to evaluate the safety,
      efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen
      receptor T cell in advanced solid tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open, multiple infusion, dose escalation/dose regimen finding study to
      assess the safety and pharmacokinetics of CAR-CLDN18.2 T cell therapy, and to obtain the
      preliminary efficacy results in subjects who have been diagnosed with advanced solid tumor
      with positive claudin 18.2 expression and failed to standard systemic treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>28 days of single infusion</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>28 days of single infusion</time_frame>
    <description>tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (the number of cell copies and cell persistence duration in peripheral blood)</measure>
    <time_frame>26 weeks</time_frame>
    <description>CAR-CLDN18.2 DNA in peripheral blood detected by q-PCR at each visit after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events occurring through 26 weeks and 12 months post infusion of CAR-CLDN18.2 T-Cell infusion, such as abnormalities or changes in laboratory examinations, physical examinations, vital signs, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The period from the day when the subject receives the infusion of cells to the first recorded tumor progression (whether treated or not) or death of any cause, which occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Duration of response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Duration of disease control (DDC)</measure>
    <time_frame>1 year</time_frame>
    <description>The period from the first evaluation of clinical benefit to the first evaluation of PD or any cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The period from the first infusion to any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%). In the event of PR or CR, the subjects should confirm it no less than 4 weeks after the first evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy-Disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>The number of cases in which response are achieved from the start of cell infusion/the total number of evaluable cases (%).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CAR-CLDN18.2 T-Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects enrolled will be sequentially assigned to the corresponding dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR-CLDN18.2 T-Cells</intervention_name>
    <description>Pretreatment with fludarabine, cyclophosphamide,
• Chimeric Antigen Receptor T Cells Targeting Claudin18.2</description>
    <arm_group_label>CAR-CLDN18.2 T-Cells</arm_group_label>
    <other_name>Chimeric Antigen Receptor T Cells Targeting Claudin18.2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 75 years, male or female;

          2. Subjects with pathologically confirmed solid tumors (ie, advanced gastric cancer,
             esophagogastric junction cancer, and pancreatic cancer) and have been failed to at
             least first-line of systemic treatment;

          3. Tumor tissue samples was positive for claudin 18.2 IHC staining;

          4. Estimated life expectancy &gt; 12 weeks;

          5. According to the RECIST 1.1, there is measurable or unmeasurable tumor lesions

          6. ECOG physical status score 0 ~ 1 at screening, within 24 hours prior to apheresis, and
             at baseline (prior to pre-treatment);

          7. Sufficient venous access for mononuclear cell collection (abbreviation: apheresis)

          8. Subjects should have adequate organ functions before screening and pre-treatment (at
             baseline).

          9. Female subjects of childbearing age must undergo a serum pregnancy test at screening
             and prior to pretreatment and the results must be negative, and are willing to use a
             very effective and reliable method of contraception within 1 year after the last study
             treatment. The methods that can be used are: bilateral tubal ligation / bilateral
             salpingectomy or bilateral tubal occlusion; or approved oral, injection or
             hormone-imparting contraceptive methods; or barrier contraceptive method: containing
             spermicidal foam / Gel/film/cream/suppository condom or occlusive cap (diaphragm or
             cervix/cap);

         10. Men who have actively sexual intercourse with women with child-bearing potential, must
             agree to use barrier-based contraception if they have no vasectomy, for example, a
             condom containing a spermicidal foam/gel/film/paste/suppository, or use a
             contraceptive method for their spouse (see article 9 of the inclusion criteria).
             Moreover, all men are absolutely forbidden to donate sperm within 1 year after
             receiving the last study treatment infusion.

        Exclusion Criteria:

          1. Pregnant or lactating women;

          2. HIV, Treponema pallidum or HCV serologically positive;

          3. Any uncontrollable active infection, including but not limited to active tuberculosis,
             HBV infection (HBsAg positive, or HBcAb positive and HBV DNA positive);

          4. Subjects have clinically significant thyroid dysfunction determined by investigator
             (serum thyroid hormone assays TT4, TT3, FT3, FT4, and serum thyroid stimulating
             hormone TSH) which is not suitable for entering into the study;

          5. The side effects caused by the previous treatment of the subjects did not return to
             CTCAE ≤1; except hair loss and other tolerable events determined by investigator;

          6. Subjects who are using steroids systemically currently within 7 days prior to
             apheresis; those using inhaled steroids recently or currently are not excluded;

          7. Previously allergic to immunotherapy and related drugs, history of severe allergies or
             allergies to components of CT041CAR-CLDN18.2T injection, allergic to β-lactam
             antibiotics;

          8. Previously received any chimeric antigen receptor-modified T-cells(including
             CAR-T、TCR-T) .

          9. Subjects have untreated or symptomatic brain metastases;

         10. Subjects have central or extensively metastases in lung and extensive metastases in
             liver.

         11. The largest single tumor lesion＞4cm

         12. Subjects have heart disease to be treated or uncontrolled hypertension after treatment
             (blood pressure &gt; 160 mmHg / 100 mmHg) ;

         13. Subjects with unstable or active ulcers and gastrointestinal bleeding currently;

         14. Subjects with a history of organ transplantation or awaiting organ transplantation;

         15. Subjects requiring anticoagulant therapy;

         16. Subjects requiring continuous anti-platelet therapy;

         17. Subjects who have undergone major surgery or significant trauma within 4 weeks prior
             to apheresis, or who are expected to undergo major surgery during the study;

         18. There are no other serious diseases that may limit subjects' participation in this
             trial

         19. The investigator assessed that the subject was unable or unwilling to comply with the
             requirements of the study protocol.

         20. Blood oxygen saturation ≤ 95% before pre-treatment (accept finger oxygen detection
             method);

         21. Prior to pretreatment, subjects developed, including but not limited to, new
             arrhythmias that could not be controlled with drugs, hypotension requiring pressor
             agent, bacterial, fungal or viral infections that required intravenous antibiotics.
             Creatinine clearance rate &lt;40mL / min; The investigator judges that the subject is not
             suitable for continuing the trial. Subjects who use antibiotics to prevent infection
             can continue the trials if judged by the investigator;

         22. The subject has a central nervous system disease sign or an abnormal neurological test
             result with clinical significance;

         23. The subject is currently suffered from or have suffered from other incurable malignant
             tumors within previous 3 years, except in situ cervical cancer or skin basal cell
             cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen</last_name>
    <phone>861088196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jifang Gong</last_name>
    <phone>861088196561</phone>
    <email>goodjf@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of GI Oncology, Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, MD,phD</last_name>
      <phone>(86)10-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jifang gong, MD,phD</last_name>
      <phone>(86)10-88196561</phone>
      <email>goodjf@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lin Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Advanced solid tumor</keyword>
  <keyword>claudin18.2</keyword>
  <keyword>CAR-T cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

